- See Also
-
Links
- “A New Drug Switched Off My Appetite. What’s Left? Mounjaro Did What Decades of Struggle With Managing Weight Couldn’t. Welcome to the Post-hunger Age”, 2023
- “Why Experts Are Urging Swifter Treatment for Children With Obesity: Growing Research Has Shown That Intensive Interventions Are Needed, Scientists Say. Here Is Why Their Advice Is Changing”, 2023
- “Two-year Effect of Semaglutide 2.4 Mg on Control of Eating in Adults With Overweight/obesity: STEP 5”, Et Al 2023
- “Once-Weekly Semaglutide in Adolescents With Obesity”, Et Al 2022
- “Eli Lilly Conference Call Summary [2022-12-13]”, 2022
- “Post-Bariatric Patients See More Benefits With Semaglutide vs Liraglutide—Semaglutide Users Also More Likely to Experience Weight Loss, Retrospective Study Suggests”, 2022
- “Weight Loss TikTok Trend Triggers Shortage of Diabetic Medication”, 2022
- “Two-year Effects of Semaglutide in Adults With Overweight or Obesity: the STEP 5 Trial”, Et Al 2022
- “Endpoints and Estimands: Understanding Trials of Weight-loss Drugs”, 2022
- “Hollywood’s Secret New Weight Loss Drug, Revealed: The Hype and Hazards of Ozempic”, 2022
- “Next Generation GLP-1/GIP/glucagon Triple Agonists Normalize Body Weight in Obese Mice”, Et Al 2022
- “The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’ Many Insurance Companies Refuse to Cover New Weight Loss Drugs That Their Doctors Deem Medically Necessary.”, 2022
- “Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: the STEP 1 Trial Extension”, Et Al 2022
- “Treatment With Glucagon-like Peptide-1 Receptor Agonists and Incidence of Dementia: Data from Pooled Double-blind Randomized Controlled Trials and Nationwide Disease and Prescription Registers”, Et Al 2022
- “Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial”, Et Al 2022
- “Once-weekly Cagrilintide for Weight Management in People With Overweight and Obesity: a Multicentre, Randomised, Double-blind, Placebo-controlled and Active-controlled, Dose-finding Phase 2 Trial”, Et Al 2021
- “Anti-obesity Drug Discovery: Advances and Challenges”, Et Al 2021
- “Wegovy™ Demonstrated Substantial and Sustained Weight Loss in Two-year Study in Adults With Obesity”, 2021
- “Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials”, Et Al 2021
- “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Concomitant Administration of Multiple Doses of Cagrilintide With Semaglutide 2·4 Mg for Weight Management: a Randomised, Controlled, Phase 1b Trial”, Et Al 2021
- “Healthy Weight Loss Maintenance With Exercise, Liraglutide, or Both Combined”, Et Al 2021
- “The Gut-brain Axis: Identifying New Therapeutic Approaches for Type 2 Diabetes, Obesity, and Related Disorders”, Et Al 2021
- “Effect of Subcutaneous Semaglutide vs Placebo As an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial”, Et Al 2021
- “Once-Weekly Semaglutide in Adults With Overweight or Obesity”, Et Al 2021
- “Amylin As a Future Obesity Treatment”, Et Al 2021
- “Efficacy and Safety of AM833 [cagrilintide] for Weight Loss: A Dose-finding Trial in Adults With Overweight/Obesity [abstract]”, Et Al 2020
- “Semaglutide 2.4 Mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5”, Et Al 2020
- “Management Of Endocrine Disease: Are All GLP-1 Agonists Equal in the Treatment of Type 2 Diabetes?”, 2019
- “Comparative Efficacy, Safety, and Cardiovascular Outcomes With Once-weekly Subcutaneous Semaglutide in the Treatment of Type 2 Diabetes: Insights from the SUSTAIN 1–7 Trials”, Et Al 2019
- “FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes”, FDA 2019
- “PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes”, Et Al 2019b
- “Oral Semaglutide versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4): a Randomised, Double-blind, Phase 3a Trial”, Et Al 2019
- “The Discovery and Development of Liraglutide and Semaglutide”, 2019
- “Glucagon Regulation of Energy Expenditure”, Et Al 2019
- “Glucagon, GLP-1 and Thermogenesis”, González- Et Al 2019
- “The Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Substance Use Disorder (SUD)-related Behavioural Effects of Drugs and Alcohol: A Systematic Review”, Et Al 2019
- “Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial”, Et Al 2019
- “Effects of Glucagon-like Peptide 1 Analogs on Alcohol Intake in Alcohol-preferring Vervet Monkeys”, Et Al 2019
- “Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects With Type 2 Diabetes”, Et Al 2018
- “Efficacy and Safety of Semaglutide Compared With Liraglutide and Placebo for Weight Loss in Patients With Obesity: a Randomised, Double-blind, Placebo and Active Controlled, Dose-ranging, Phase 2 Trial”, Et Al 2018
- “Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial”, Et Al 2017
- “Effects of Once-weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity”, Et Al 2017
- “Unimolecular Polypharmacy for Treatment of Diabetes and Obesity”, Et Al 2016
- “A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes”, Et Al 2016
- “Glucagon Increases Energy Expenditure Independently of Brown Adipose Tissue Activation in Humans”, Et Al 2016
- “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide”, Et Al 2015
- “An Overview of Once-weekly Glucagon-like Peptide-1 Receptor Agonists—available Efficacy and Safety Data and Perspectives for the Future”, Et Al 2011
- “Society Is Fixed, Biology Is Mutable”
- Wikipedia
- Miscellaneous
- Link Bibliography
See Also
Links
“A New Drug Switched Off My Appetite. What’s Left? Mounjaro Did What Decades of Struggle With Managing Weight Couldn’t. Welcome to the Post-hunger Age”, 2023
“A New Drug Switched Off My Appetite. What’s Left? Mounjaro did what decades of struggle with managing weight couldn’t. Welcome to the post-hunger age”, 2023-02-03 (; similar)
“Why Experts Are Urging Swifter Treatment for Children With Obesity: Growing Research Has Shown That Intensive Interventions Are Needed, Scientists Say. Here Is Why Their Advice Is Changing”, 2023
“Why Experts Are Urging Swifter Treatment for Children With Obesity: Growing research has shown that intensive interventions are needed, scientists say. Here is why their advice is changing”, 2023-01-27 (similar)
“Two-year Effect of Semaglutide 2.4 Mg on Control of Eating in Adults With Overweight/obesity: STEP 5”, Et Al 2023
“Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5”, 2023-01-18 (; similar)
“Once-Weekly Semaglutide in Adolescents With Obesity”, Et Al 2022
“Once-Weekly Semaglutide in Adolescents with Obesity”, 2022-12-15 (similar)
“Eli Lilly Conference Call Summary [2022-12-13]”, 2022
“Eli Lilly conference call summary [2022-12-13]”, 2022-12-13 (similar)
“Post-Bariatric Patients See More Benefits With Semaglutide vs Liraglutide—Semaglutide Users Also More Likely to Experience Weight Loss, Retrospective Study Suggests”, 2022
“Post-Bariatric Patients See More Benefits With Semaglutide vs Liraglutide—Semaglutide users also more likely to experience weight loss, retrospective study suggests”, 2022-11-03 (similar)
“Weight Loss TikTok Trend Triggers Shortage of Diabetic Medication”, 2022
“Weight loss TikTok trend triggers shortage of diabetic medication”, 2022-10-31 (similar)
“Two-year Effects of Semaglutide in Adults With Overweight or Obesity: the STEP 5 Trial”, Et Al 2022
“Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial”, 2022-10-10 (backlinks; similar)
“Endpoints and Estimands: Understanding Trials of Weight-loss Drugs”, 2022
“Hollywood’s Secret New Weight Loss Drug, Revealed: The Hype and Hazards of Ozempic”, 2022
“Hollywood’s Secret New Weight Loss Drug, Revealed: The Hype and Hazards of Ozempic”, 2022-10 (similar)
“Next Generation GLP-1/GIP/glucagon Triple Agonists Normalize Body Weight in Obese Mice”, Et Al 2022
“Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice”, 2022-07-07 (similar; bibliography)
“The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’ Many Insurance Companies Refuse to Cover New Weight Loss Drugs That Their Doctors Deem Medically Necessary.”, 2022
“The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’ Many insurance companies refuse to cover new weight loss drugs that their doctors deem medically necessary.”, 2022-05-31 (similar)
“Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: the STEP 1 Trial Extension”, Et Al 2022
“Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension”, 2022-04-19 (similar)
“Treatment With Glucagon-like Peptide-1 Receptor Agonists and Incidence of Dementia: Data from Pooled Double-blind Randomized Controlled Trials and Nationwide Disease and Prescription Registers”, Et Al 2022
“Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers”, 2022-02-23 (; similar)
“Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial”, Et Al 2022
“Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial”, 2022-01-11 (similar)
“Once-weekly Cagrilintide for Weight Management in People With Overweight and Obesity: a Multicentre, Randomised, Double-blind, Placebo-controlled and Active-controlled, Dose-finding Phase 2 Trial”, Et Al 2021
“Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial”, 2021-12-11 (backlinks; similar; bibliography)
“Anti-obesity Drug Discovery: Advances and Challenges”, Et Al 2021
“Anti-obesity drug discovery: advances and challenges”, 2021-11-23 (; similar)
“Wegovy™ Demonstrated Substantial and Sustained Weight Loss in Two-year Study in Adults With Obesity”, 2021
“Wegovy™ demonstrated substantial and sustained weight loss in two-year study in adults with obesity”, 2021-11-05 (similar)
“Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials”, Et Al 2021
“Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials”, 2021-05-10 (backlinks; similar; bibliography)
“Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Concomitant Administration of Multiple Doses of Cagrilintide With Semaglutide 2·4 Mg for Weight Management: a Randomised, Controlled, Phase 1b Trial”, Et Al 2021
“Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial”, 2021-05-08 (similar; bibliography)
“Healthy Weight Loss Maintenance With Exercise, Liraglutide, or Both Combined”, Et Al 2021
“Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined”, 2021-05-06 (; similar; bibliography)
“The Gut-brain Axis: Identifying New Therapeutic Approaches for Type 2 Diabetes, Obesity, and Related Disorders”, Et Al 2021
“The gut-brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders”, 2021-04 (similar; bibliography)
“Effect of Subcutaneous Semaglutide vs Placebo As an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial”, Et Al 2021
“Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial”, 2021-02-24 (similar)
“Once-Weekly Semaglutide in Adults With Overweight or Obesity”, Et Al 2021
“Once-Weekly Semaglutide in Adults with Overweight or Obesity”, 2021-02-10 (backlinks; similar)
“Amylin As a Future Obesity Treatment”, Et Al 2021
“Amylin as a Future Obesity Treatment”, 2021 (backlinks; similar)
“Efficacy and Safety of AM833 [cagrilintide] for Weight Loss: A Dose-finding Trial in Adults With Overweight/Obesity [abstract]”, Et Al 2020
“Efficacy and Safety of AM833 [cagrilintide] for Weight Loss: A Dose-finding Trial in Adults With Overweight/Obesity [abstract]”, 2020-11-04 (similar)
“Semaglutide 2.4 Mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5”, Et Al 2020
“Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5”, 2020-05-22 (similar; bibliography)
“Management Of Endocrine Disease: Are All GLP-1 Agonists Equal in the Treatment of Type 2 Diabetes?”, 2019
“Management Of Endocrine Disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?”, 2019-12-01 (similar)
“Comparative Efficacy, Safety, and Cardiovascular Outcomes With Once-weekly Subcutaneous Semaglutide in the Treatment of Type 2 Diabetes: Insights from the SUSTAIN 1–7 Trials”, Et Al 2019
“Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials”, 2019-10-01 (similar)
“FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes”, FDA 2019
“FDA approves first oral GLP-1 treatment for type 2 diabetes”, 2019-09-20 (; similar)
“PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes”, Et Al 2019b
“PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes”, 2019-09-01 (backlinks; similar)
“Oral Semaglutide versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4): a Randomised, Double-blind, Phase 3a Trial”, Et Al 2019
“Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial”, 2019-07-06 (backlinks; similar)
“The Discovery and Development of Liraglutide and Semaglutide”, 2019
“The Discovery and Development of Liraglutide and Semaglutide”, 2019-04-12 (similar)
“Glucagon Regulation of Energy Expenditure”, Et Al 2019
“Glucagon Regulation of Energy Expenditure”, 2019 (backlinks)
“Glucagon, GLP-1 and Thermogenesis”, González- Et Al 2019
“Glucagon, GLP-1 and Thermogenesis”, 2019 (backlinks; similar)
“The Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Substance Use Disorder (SUD)-related Behavioural Effects of Drugs and Alcohol: A Systematic Review”, Et Al 2019
“The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review”, 2019 (; similar)
“Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial”, Et Al 2019
“Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial”, 2019 (backlinks; similar)
“Effects of Glucagon-like Peptide 1 Analogs on Alcohol Intake in Alcohol-preferring Vervet Monkeys”, Et Al 2019
“Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys”, 2019 (; similar)
“Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects With Type 2 Diabetes”, Et Al 2018
“Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes”, 2018-12-18 (backlinks; similar)
“Efficacy and Safety of Semaglutide Compared With Liraglutide and Placebo for Weight Loss in Patients With Obesity: a Randomised, Double-blind, Placebo and Active Controlled, Dose-ranging, Phase 2 Trial”, Et Al 2018
“Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial”, 2018-08-16 (similar)
“Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial”, Et Al 2017
“Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial”, 2017-10-17 (similar; bibliography)
“Effects of Once-weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity”, Et Al 2017
“Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity”, 2017-03-07 (; similar)
“Unimolecular Polypharmacy for Treatment of Diabetes and Obesity”, Et Al 2016
“Unimolecular Polypharmacy for Treatment of Diabetes and Obesity”, 2016-07-12 (backlinks; similar)
“A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes”, Et Al 2016
“A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes”, 2016-02-01 (similar)
“Glucagon Increases Energy Expenditure Independently of Brown Adipose Tissue Activation in Humans”, Et Al 2016
“Glucagon increases energy expenditure independently of brown adipose tissue activation in humans”, 2016 (backlinks; similar)
“Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide”, Et Al 2015
“Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide”, 2015-08-26 (similar)
“An Overview of Once-weekly Glucagon-like Peptide-1 Receptor Agonists—available Efficacy and Safety Data and Perspectives for the Future”, Et Al 2011
“An overview of once-weekly glucagon-like peptide-1 receptor agonists—available efficacy and safety data and perspectives for the future”, 2011-01-05 (similar)
“Society Is Fixed, Biology Is Mutable”
Wikipedia
Miscellaneous
-
https://astralcodexten.substack.com/p/highlights-from-the-comments-on-semaglutide -
https://chadnauseam.com/random/semaglutide-has-changed-the-world/ -
https://nitter.moomoo.me/DanielJDrucker/status/1591171488002232320 -
https://nitter.moomoo.me/DrNadolsky/status/1628436158400135169 -
https://nitter.moomoo.me/RosieCampbell/status/1636050117202694144 -
https://trevorklee.com/should-you-take-metformin-for-longevity/ -
https://trevorklee.substack.com/p/obesitys-relationship-with-type-2
Link Bibliography
-
https://www.sciencedirect.com/science/article/pii/S2212877822001028: “Next Generation GLP-1 / GIP / glucagon Triple Agonists Normalize Body Weight in Obese Mice”, : -
https://link.springer.com/article/10.1007/s40262-021-01025-x: “Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials”, Rune V. Overgaard, Andrea Navarria, Steen H. Ingwersen, Tine A. Bækdal, Rasmus Juul Kildemoes: -
2021-lundgren.pdf: “Healthy Weight Loss Maintenance With Exercise, Liraglutide, or Both Combined”, : -
https://www.sciencedirect.com/science/article/pii/S2212877821000156: “The Gut-brain Axis: Identifying New Therapeutic Approaches for Type 2 Diabetes, Obesity, and Related Disorders”, Paul Richards, Nancy A. Thornberry, Shirly Pinto: -
2020-kushner.pdf: “Semaglutide 2.4 Mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5”, : -
2017-davies.pdf: “Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial”, Melanie Davies, Thomas R. Pieber, Marie-Louise Hartoft-Nielsen, Oluf K. H. Hansen, Serge Jabbour, Julio Rosenstock: